Publications in collaboration with researchers from Hospital Virgen de la Arrixaca (45)

2026

  1. Corrigendum to “Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery” [Gynecol Oncol. 2026 Apr;207:16-22. doi:10.1016/j.ygyno.2026.02.014. Epub 2026 Feb 25. PMID: 41747472] (Gynecologic Oncology (2026) 207 (16–22), (S0090825826008085), (10.1016/j.ygyno.2026.02.014))

    Gynecologic Oncology

  2. Neoadjuvant Chemotherapy Following Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Retrospective Cohort Study

    Cancers, Vol. 18, Núm. 5

  3. Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

    British Journal of Cancer, Vol. 134, Núm. 12, pp. 1754-1763

  4. Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery

    Gynecologic Oncology, Vol. 207, pp. 16-22

  5. Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer

    Breast Cancer Research and Treatment, Vol. 215, Núm. 2

2025

  1. Challenges of Nontherapeutic Laparotomy in Patients with Peritoneal Surface Malignancies Selected for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

    Cancers, Vol. 17, Núm. 9

  2. Combined Hyperthermic Intraperitoneal Chemotherapy and Normothermic Intraperitoneal Chemotherapy Long-Term After Interval Cytoreduction in Ovarian Cancer: A Phase I Clinical Trial (BICOV1)

    Cancers, Vol. 17, Núm. 12

  3. Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation

    The oncologist, Vol. 30, Núm. 5

  4. Peritoneal cancer index in ovarian cancer: what does the surgeon really see?

    Clinical and Translational Oncology, Vol. 27, Núm. 11, pp. 4185-4191

  5. SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024)

    Clinical and Translational Oncology, Vol. 27, Núm. 4, pp. 1460-1471

  6. Tratamientos

    Diseño de programas de ejercicio físico en población oncológica (Síntesis), pp. 63-125

  7. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

    Pharmaceuticals, Vol. 18, Núm. 12

  8. [Translated article] Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers

    Actas Dermo-Sifiliograficas

2024

  1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 403, Núm. 10421, pp. 31-43

  2. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Gynecologic Oncology, Vol. 185, pp. 202-211

  3. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

    Pharmaceutics, Vol. 16, Núm. 12

  4. Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience from 2 Tertiary Referral Centers

    Actas Dermo-Sifiliograficas

  5. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab 6 olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial

    Journal of Clinical Oncology, Vol. 42, Núm. 16

  6. Systematic Cholecystectomy During Cytoreductive Surgery Plus HIPEC: A Critical Analysis of an Empirical Tradition

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 7157-7164

2023

  1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778